drugset / Trial / NCT02192489
A Phase 2 Study With CC-220 in Skin Sarcoidosis
RandomizedSingle-groupQuadruple-blindTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.
Timeline
- Start
- 2014-11-01
- Primary completion
- 2017-06-30
- Completion
- 2017-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iberdomide | Small molecule | 0.3 mg | Oral |
| Subject | Iberdomide | Small molecule | 0.6 mg | Oral |